Terms: = Breast cancer AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K AND Treatment
2404 results:
1. The Significance of Thyroid Hormone Receptors in breast cancer: A Hypothesis-Generating Narrative Review.
Quan T; Cockburn J; Dhesy-Thind S; Bane A; Leong H; Geleff C; Devion C; Ajel N; Jerzak KJ
Curr Oncol; 2024 Apr; 31(5):2364-2375. PubMed ID: 38785457
[TBL] [Abstract] [Full Text] [Related]
2. Enhancing pathological complete response prediction in breast cancer: the role of dynamic characterization of DCE-MRI and its association with tumor heterogeneity.
Zhang X; Teng X; Zhang J; Lai Q; Cai J
Breast Cancer Res; 2024 May; 26(1):77. PubMed ID: 38745321
[TBL] [Abstract] [Full Text] [Related]
3. Proteogenomic characterization of difficult-to-treat breast cancer with tumor cells enriched through laser microdissection.
Raj-Kumar PK; Lin X; Liu T; Sturtz LA; Gritsenko MA; Petyuk VA; Sagendorf TJ; Deyarmin B; Liu J; Praveen-Kumar A; Wang G; McDermott JE; Shukla AK; Moore RJ; Monroe ME; Webb-Robertson BM; Hooke JA; Fantacone-Campbell L; Mostoller B; Kvecher L; Kane J; Melley J; Somiari S; Soon-Shiong P; Smith RD; Mural RJ; Rodland KD; Shriver CD; Kovatich AJ; Hu H
Breast Cancer Res; 2024 May; 26(1):76. PubMed ID: 38745208
[TBL] [Abstract] [Full Text] [Related]
4. Mechanistic exploration and experimental validation of the Xiaochaihu decoction for the treatment of breast cancer by network pharmacology.
Liu Q; Luo Z; Sun M; Li W; Liu S
Aging (Albany NY); 2024 May; 16(9):7979-7999. PubMed ID: 38742934
[TBL] [Abstract] [Full Text] [Related]
5. The combination of breast cancer PDO and mini-PDX platform for drug screening and individualized treatment.
Cui Y; Ran R; Da Y; Zhang H; Jiang M; Qi X; Zhang W; Niu L; Zhou Y; Zhou C; Tang X; Wang K; Yan Y; Ren Y; Dong D; Zhou Y; Wang H; Gong J; Hu F; Zhao S; Zhang H; Zhang C; Yang J
J Cell Mol Med; 2024 May; 28(9):e18374. PubMed ID: 38722288
[TBL] [Abstract] [Full Text] [Related]
6. The Human Intermediate Prolactin Receptor I-tail Contributes breast Oncogenesis by Targeting Ras/MAPK Pathway.
Shen S; Radhakrishnan SK; Harrell JC; Puchalapalli M; Koblinski J; Clevenger C
Endocrinology; 2024 Apr; 165(6):. PubMed ID: 38713636
[TBL] [Abstract] [Full Text] [Related]
7. pDNA-tachyplesin treatment stimulates the immune system and increases the probability of apoptosis in MC4-L2 tumor cells.
Mahmoudi-Filabadi F; Doosti A
Amino Acids; 2024 May; 56(1):34. PubMed ID: 38691208
[TBL] [Abstract] [Full Text] [Related]
8. Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human breast cancer.
Wescott EC; Sun X; Gonzalez-Ericsson P; Hanna A; Taylor BC; Sanchez V; Bronzini J; Opalenik SR; Sanders ME; Wulfkuhle J; Gallagher RI; Gomez H; Isaacs C; Bharti V; Wilson JT; Ballinger TJ; Santa-Maria CA; Shah PD; Dees EC; Lehmann BD; Abramson VG; Hirst GL; Brown Swigart L; van ˈt Veer LJ; Esserman LJ; Petricoin EF; Pietenpol JA; Balko JM
Cancer Res Commun; 2024 Apr; 4(4):1120-1134. PubMed ID: 38687247
[TBL] [Abstract] [Full Text] [Related]
9. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
10. Design, Synthesis, Formulation, and Bioevaluation of Trisubstituted Triazines as Highly Selective mTOR Inhibitors for the treatment of Human breast cancer.
Sun Q; Chu Y; Zhang N; Chen R; Wang L; Wu J; Dong Y; Li H; Wang L; Tang L; Zhan C; Zhang JQ
J Med Chem; 2024 May; 67(9):7330-7358. PubMed ID: 38661655
[TBL] [Abstract] [Full Text] [Related]
11. Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Metastatic breast cancer Treated With Abemaciclib: Data From the SCRUM-Japan cancer Genome Screening Project.
Hattori M; Serelli-Lee V; Naito Y; Yamanaka T; Yasojima H; Nakamura R; Fujisawa T; Imai M; Nakamura Y; Bando H; Kawaguchi T; Yoshino T; Iwata H
JCO Precis Oncol; 2024 Apr; 8():e2300647. PubMed ID: 38635933
[TBL] [Abstract] [Full Text] [Related]
12. Exploring the therapeutic potential of tonic Chinese herbal medicine for gynecological disorders: An updated review.
He Q; Wan S; Jiang M; Li W; Zhang Y; Zhang L; Wu M; Lin J; Zou L; Hu Y
J Ethnopharmacol; 2024 Jul; 329():118144. PubMed ID: 38583732
[TBL] [Abstract] [Full Text] [Related]
13. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN; Chung YS; Park E; Lee ST; Lee JY
Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
[TBL] [Abstract] [Full Text] [Related]
14. Exploring the effectiveness of molecular subtypes, biomarkers, and genetic variations as first-line treatment predictors in Asian breast cancer patients: a systematic review and meta-analysis.
Bahrin NWS; Matusin SNI; Mustapa A; Huat LZ; Perera S; Hamid MRWHA
Syst Rev; 2024 Apr; 13(1):100. PubMed ID: 38576013
[TBL] [Abstract] [Full Text] [Related]
15. Lapatinib antitumor effect is associated with pi3k and MAPK pathway: An analysis in human and canine prostate cancer cells.
Fonseca-Alves CE; Leis-Filho AF; Lacerda ZA; de Faria Lainetti P; Amorim RL; Rogatto SR
PLoS One; 2024; 19(4):e0297043. PubMed ID: 38564578
[TBL] [Abstract] [Full Text] [Related]
16. Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
Layman RM; Han HS; Rugo HS; Stringer-Reasor EM; Specht JM; Dees EC; Kabos P; Suzuki S; Mutka SC; Sullivan BF; Gorbatchevsky I; Wesolowski R
Lancet Oncol; 2024 Apr; 25(4):474-487. PubMed ID: 38547892
[TBL] [Abstract] [Full Text] [Related]
17. Regulation of inflammatory response by LINC00346 via miR-25-3p-mediated modulation of the PTEN/pi3k/AKT/NF-κB pathway.
Kim MJ; Lim SG; Cho DH; Lee JY; Suk K; Lee WH
Biochem Biophys Res Commun; 2024 May; 709():149828. PubMed ID: 38537596
[TBL] [Abstract] [Full Text] [Related]
18. Characterizing the Efficacy and Safety of Chemotherapy Plus Everolimus in HER2-Negative Metastatic breast cancer Harboring Altered pi3k/AKT/mTOR.
Wang R; Zhu QY; Ye WW; Huang Y; Chen ZH; Zheng YB; Zou X; Wang J; Jiang DL; Wang XJ; Xu ZY; Cao WM
Discov Med; 2024 Mar; 36(182):527-537. PubMed ID: 38531793
[TBL] [Abstract] [Full Text] [Related]
19. Morusin inhibits breast cancer-induced osteolysis by decreasing phosphatidylinositol 3-kinase (pi3k)-mTOR signalling.
Zhang L; Li W; Chen X; Cao D; You S; Shi F; Luo Z; Li H; Zeng X; Song Y; Li N; Akimoto Y; Rui G; Chen Y; Wu Z; Xu R
Chem Biol Interact; 2024 May; 394():110968. PubMed ID: 38522564
[TBL] [Abstract] [Full Text] [Related]
20. Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic breast cancer Patients.
Canino F; Tornincasa A; Bettelli S; Manfredini S; Barbolini M; Moscetti L; Omarini C; Toss A; Tamburrano F; Antonelli G; Baglio F; Belluzzi L; Martinelli G; Natalizio S; Ponzoni O; Dominici M; Piacentini F
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473737
[TBL] [Abstract] [Full Text] [Related]
[Next]
